Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia (RESTORE-CLI)

This study has been completed.
Information provided by (Responsible Party):
Vericel Corporation Identifier:
First received: April 30, 2007
Last updated: June 29, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 24, 2016